Lifecore Biomedical (LFCR) Financials

Lifecore Biomedical logo
$6.40 -0.01 (-0.08%)
As of 12:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Lifecore Biomedical

Annual Income Statements for Lifecore Biomedical

This table shows Lifecore Biomedical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
Net Income / (Loss) Attributable to Common Shareholders
14 -12 11 25 0.41 -38 -32 -117 -100 12 -44
Consolidated Net Income / (Loss)
14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Net Income / (Loss) Continuing Operations
14 -12 10 26 2.12 -22 -23 -15 -64 9.33 -39
Total Pre-Tax Income
21 -20 14 16 3.64 -31 -30 -21 -64 9.51 -39
Total Operating Income
18 -21 15 14 5.48 -26 -8.82 -12 -22 -8.84 -17
Total Gross Profit
65 67 79 78 81 39 39 39 28 42 40
Total Revenue
539 477 470 524 558 160 101 111 103 128 129
Operating Revenue
539 477 470 524 558 160 101 111 103 128 129
Total Cost of Revenue
474 410 391 446 477 121 62 72 75 86 89
Operating Cost of Revenue
474 410 391 446 477 121 62 72 75 86 89
Total Operating Expenses
47 87 65 65 76 65 48 51 50 51 58
Selling, General & Admin Expense
40 46 52 52 62 41 28 35 39 40 44
Research & Development Expense
6.99 7.23 9.47 13 11 7.58 6.68 7.84 8.74 8.58 8.26
Restructuring Charge
- - - 0.00 0.00 4.05 13 8.36 4.18 1.66 -1.75
Other Special Charges / (Income)
0.00 0.00 2.58 - 0.00 0.00 - - - 0.00 6.99
Total Other Income / (Expense), net
3.01 0.93 -0.49 2.81 -1.84 -4.77 -21 -8.90 -42 18 -21
Interest & Investment Income
1.73 1.72 1.67 1.86 1.80 0.07 0.05 - - -18 -22
Other Income / (Expense), net
3.11 1.20 0.90 2.90 1.60 -0.20 -11 6.57 -0.81 36 0.41
Income Tax Expense
7.75 -7.70 4.04 -9.36 1.52 -8.77 -6.35 -5.21 0.31 0.18 0.04
Net Income / (Loss) Discontinued Operations
- 0.54 0.54 -0.84 -1.71 -16 -8.86 -101 -35 2.68 0.00
Preferred Stock Dividends Declared
- - - - - - - - - 0.00 5.64
Basic Earnings per Share
$0.50 ($0.43) $0.39 $0.90 $0.01 ($1.31) ($1.10) ($3.97) ($3.32) $0.39 ($1.27)
Weighted Average Basic Shares Outstanding
26.88M 27.04M 27.28M 27.54M 28.36M 29.16M 29.29M 29.47M 29.96M 30.47M 34.82M
Diluted Earnings per Share
$0.50 ($0.43) $0.38 $0.89 $0.01 ($1.31) ($1.10) ($3.97) ($3.32) $0.33 ($1.27)
Weighted Average Diluted Shares Outstanding
27.34M 27.04M 27.65M 27.92M 28.61M 29.16M 29.29M 29.47M 29.96M 36.66M 34.82M
Weighted Average Basic & Diluted Shares Outstanding
27.10M 27.10M 27.20M 27.60M 41.10M 29.24M 29.46M - - 30.90M 37.41M

Quarterly Income Statements for Lifecore Biomedical

This table shows Lifecore Biomedical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 5/25/2025 9/30/2025 5/25/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-11 14 16 -7.08 -16 -2.05 -11 -2.05 -16 -7.13 -41
Consolidated Net Income / (Loss)
-11 14 16 -7.08 -16 -1.15 -9.99 -1.15 -15 -6.16 -40
Net Income / (Loss) Continuing Operations
-13 14 15 -7.09 -16 -1.15 -9.99 -1.15 -15 -6.16 -40
Total Pre-Tax Income
-13 14 15 -7.14 -16 -1.11 -9.66 -1.11 -15 -6.13 -40
Total Operating Income
-8.61 -1.48 -0.90 2.15 -12 5.33 -3.07 5.33 -4.67 2.57 -0.89
Total Gross Profit
2.73 9.96 12 17 5.39 14 7.79 14 4.46 12 6.83
Total Revenue
25 30 36 38 25 36 31 36 23 34 25
Operating Revenue
25 30 36 38 25 36 31 36 23 34 25
Total Cost of Revenue
22 20 24 21 19 22 23 22 19 22 18
Operating Cost of Revenue
22 20 24 21 19 22 23 22 19 22 18
Total Operating Expenses
11 11 13 15 17 8.66 11 8.66 9.13 9.51 7.72
Selling, General & Admin Expense
9.20 9.34 9.85 12 15 8.98 8.90 8.05 7.92 7.97 6.30
Research & Development Expense
2.15 2.10 2.17 2.16 2.19 2.10 1.96 2.10 1.22 1.54 1.42
Restructuring Charge
- - 0.77 0.74 - -2.52 0.00 - - 0.00 0.00
Other Special Charges / (Income)
- - 0.00 - - 0.09 0.00 - 0.00 0.00 0.00
Total Other Income / (Expense), net
-3.91 16 16 -9.29 -4.67 -6.44 -6.59 -6.44 -10 -8.70 -39
Interest Expense
3.94 4.07 - 5.79 5.38 5.73 6.38 - 7.35 7.75 8.10
Interest & Investment Income
- - -4.29 - 0.02 0.21 0.06 - 0.13 0.14 0.23
Other Income / (Expense), net
0.03 20 20 -3.50 0.70 -0.92 -0.27 -0.92 -3.05 -1.09 -31
Income Tax Expense
0.09 -0.07 0.22 -0.06 -0.03 0.03 0.33 0.03 0.04 0.02 0.05
Preferred Stock Dividends Declared
- 0.00 0.00 - 0.00 0.90 0.92 - 0.95 0.97 0.94
Basic Earnings per Share
($0.35) $0.47 $0.51 ($0.23) ($0.53) ($0.06) ($0.29) ($0.02) ($0.43) ($0.19) ($1.08)
Weighted Average Basic Shares Outstanding
30.40M 30.46M 30.49M 30.47M 30.86M 37.01M 37.40M 34.82M 37.48M 37.57M 37.85M
Diluted Earnings per Share
($0.35) $0.39 $0.42 ($0.14) ($0.53) ($0.06) ($0.29) ($0.02) ($0.43) ($0.19) ($1.08)
Weighted Average Diluted Shares Outstanding
30.40M 36.42M 36.61M 36.66M 30.86M 37.01M 37.40M 34.82M 37.48M 37.57M 37.85M
Weighted Average Basic & Diluted Shares Outstanding
- - - 30.90M 30.90M 37.03M 37.03M 37.41M 37.51M 37.85M 37.91M

Annual Cash Flow Statements for Lifecore Biomedical

This table details how cash moves in and out of Lifecore Biomedical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
Net Change in Cash & Equivalents
-0.12 -4.23 -4.39 -2.52 -1.75 -0.91 0.74 0.35 17 -11 -0.20
Net Cash From Operating Activities
27 21 30 20 16 -17 16 -23 -17 0.26 -0.21
Net Cash From Continuing Operating Activities
27 21 30 20 16 -17 16 -23 -17 0.26 -0.21
Net Income / (Loss) Continuing Operations
14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Consolidated Net Income / (Loss)
14 -11 11 25 0.41 -38 -32 -117 -100 12 -39
Depreciation Expense
7.09 9.40 11 12 15 19 20 18 13 7.95 8.03
Non-Cash Adjustments To Reconcile Net Income
-1.62 36 4.88 1.66 4.57 36 27 86 49 24 33
Changes in Operating Assets and Liabilities, net
7.40 -13 3.60 -19 -4.19 -33 1.89 -9.93 20 -44 -2.19
Net Cash From Investing Activities
-34 -40 -25 -36 -97 -24 -12 80 -4.81 -18 -6.42
Net Cash From Continuing Investing Activities
-34 -40 -25 -36 -97 -24 -12 80 -4.81 -18 -6.42
Purchase of Property, Plant & Equipment
-18 -40 -23 -34 -45 -27 -25 -30 -21 -18 -13
Sale of Property, Plant & Equipment
1.07 0.13 0.08 0.10 0.26 2.43 13 1.14 0.00 0.00 7.00
Net Cash From Financing Activities
7.71 15 -8.80 13 79 40 -3.42 -57 40 7.51 6.42
Net Cash From Continuing Financing Activities
7.71 15 -8.80 13 79 40 -3.42 -57 40 7.51 6.42
Repayment of Debt
-37 -37 -63 -14 -40 -107 -273 -131 -184 -148 -147
Issuance of Debt
45 53 55 33 119 147 270 75 181 150 129
Issuance of Common Equity
0.12 0.32 0.71 0.06 0.33 0.03 0.00 0.00 4.82 0.00 24
Other Financing Activities, net
-0.34 -0.25 -0.48 -5.57 -0.70 -0.21 -0.41 -0.79 -0.27 5.57 1.13

Quarterly Cash Flow Statements for Lifecore Biomedical

This table details how cash moves in and out of Lifecore Biomedical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 11/24/2024 2/23/2025 5/25/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-10 -5.42 -0.15 5.39 -2.94 3.94 -4.04 2.85 3.33 -3.55 5.79
Net Cash From Operating Activities
-8.33 1.29 -1.42 8.64 -0.61 -6.11 1.20 5.35 4.70 -2.19 6.95
Net Cash From Continuing Operating Activities
-8.33 1.29 -1.42 8.64 -0.61 -6.11 1.20 5.35 4.70 -2.19 6.95
Net Income / (Loss) Continuing Operations
-11 14 16 -7.08 -16 -6.57 -15 -1.15 -15 -6.16 -40
Consolidated Net Income / (Loss)
-11 14 16 -7.08 -16 -6.57 -15 -1.15 -15 -6.16 -40
Depreciation Expense
2.17 1.77 2.01 2.25 1.99 2.04 2.08 1.91 2.31 2.52 2.41
Non-Cash Adjustments To Reconcile Net Income
4.58 5.25 6.93 6.58 6.97 8.20 14 3.69 12 5.71 5.10
Changes in Operating Assets and Liabilities, net
-4.33 -20 -26 6.89 6.65 -9.79 0.23 0.89 5.48 -4.26 40
Net Cash From Investing Activities
-5.05 -4.26 -6.37 -2.64 -3.42 -2.47 1.54 -2.10 -1.12 -0.51 -0.91
Net Cash From Continuing Investing Activities
-5.05 -4.26 -6.37 -2.64 -3.42 -2.47 1.54 -2.10 -1.12 -0.51 -0.91
Purchase of Property, Plant & Equipment
-5.05 -4.26 -6.37 -2.64 -3.42 -2.47 -5.46 -2.10 -1.12 -0.51 -0.91
Net Cash From Financing Activities
2.93 -2.45 7.64 -0.61 1.09 13 -6.78 -0.40 -0.26 -0.85 -0.24
Net Cash From Continuing Financing Activities
2.93 -2.45 7.64 -0.61 1.09 13 -6.78 -0.40 -0.26 -0.85 -0.24
Repayment of Debt
0.00 -0.12 2.62 -150 -30 -11 -6.75 -129 -37 -28 -37
Issuance of Debt
2.28 - - 150 32 - - - 36 28 36
Other Financing Activities, net
0.65 -0.04 5.02 -0.09 -0.59 1.97 -0.05 -0.16 0.00 -0.61 -0.00

Annual Balance Sheets for Lifecore Biomedical

This table presents Lifecore Biomedical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 12/31/2025
Total Assets
346 343 359 405 519 541 502 275 254 254 232
Total Current Assets
93 86 81 97 133 157 145 117 94 81 82
Cash & Equivalents
14 9.89 6.00 2.90 1.08 0.36 0.76 0.99 19 8.46 17
Accounts Receivable
46 46 46 54 70 76 32 38 29 27 26
Inventories, net
25 26 24 32 54 66 34 36 41 40 29
Prepaid Expenses
5.46 4.47 3.50 7.96 8.26 14 1.50 2.05 4.92 1.44 1.92
Other Current Assets
- - - - - - - - - 4.07 7.66
Plant, Property, & Equipment, net
84 121 133 160 200 192 107 119 134 149 127
Total Noncurrent Assets
169 135 144 148 186 192 204 39 25 24 23
Goodwill
50 50 55 55 77 69 14 14 14 14 14
Other Noncurrent Operating Assets
63 64 67 72 64 84 17 8.44 7.20 5.68 8.70
Total Liabilities & Shareholders' Equity
346 343 359 405 519 541 502 275 254 254 232
Total Liabilities
126 130 130 152 249 310 300 187 218 200 198
Total Current Liabilities
56 56 51 88 137 164 102 177 39 39 24
Accounts Payable
35 31 25 35 54 52 12 13 22 16 6.21
Accrued Expenses
5.21 7.77 9.05 8.71 10 9.98 3.01 6.48 7.14 23 17
Total Noncurrent Liabilities
70 74 79 64 112 146 198 10 179 161 175
Long-Term Debt
34 46 42 37 87 101 165 0.00 101 124 141
Other Noncurrent Operating Liabilities
1.69 1.74 8.39 5.28 5.27 31 20 7.85 75 37 33
Commitments & Contingencies
- - - - - - - - 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - 0.00 0.00 39 43 48
Total Equity & Noncontrolling Interests
220 212 228 253 270 231 202 88 -4.23 11 -14
Total Preferred & Common Equity
218 211 227 253 270 231 202 88 -4.23 11 -14
Total Common Equity
218 211 227 253 270 231 202 88 -4.23 11 -14
Common Stock
133 137 142 142 160 163 166 167 174 178 209
Retained Earnings
85 73 84 109 110 71 38 -79 -179 -167 -223

Quarterly Balance Sheets for Lifecore Biomedical

This table presents Lifecore Biomedical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 8/25/2024 11/24/2024 2/23/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
246 246 246 247 255 238 225 230 228
Total Current Assets
83 77 76 74 82 84 78 84 85
Cash & Equivalents
8.64 3.22 3.07 5.52 9.46 5.42 21 17 23
Accounts Receivable
27 30 31 25 30 28 19 30 21
Inventories, net
42 41 40 42 39 35 28 25 28
Prepaid Expenses
5.87 1.85 1.97 1.88 2.89 2.55 1.80 2.95 2.60
Other Current Assets
- - - - - 6.15 7.45 7.57 10
Plant, Property, & Equipment, net
136 143 145 149 151 128 126 124 122
Total Noncurrent Assets
27 26 25 24 23 25 22 22 22
Goodwill
14 14 14 14 14 14 14 14 14
Other Noncurrent Operating Assets
8.47 8.11 6.64 5.80 4.87 7.18 8.47 8.21 7.70
Total Liabilities & Shareholders' Equity
246 246 246 247 255 238 225 230 228
Total Liabilities
219 203 187 207 196 190 205 213 251
Total Current Liabilities
35 40 37 41 35 31 20 22 22
Accounts Payable
16 19 16 18 15 7.41 7.01 7.53 8.59
Accrued Expenses
4.86 7.66 8.89 11 9.87 20 13 14 13
Total Noncurrent Liabilities
184 163 150 167 160 159 184 192 229
Long-Term Debt
107 109 116 127 119 124 148 154 160
Other Noncurrent Operating Liabilities
74 54 33 34 36 35 36 38 69
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
40 41 42 43 44 45 49 50 51
Total Equity & Noncontrolling Interests
-14 1.42 18 -3.94 15 2.23 -28 -34 -73
Total Preferred & Common Equity
-14 1.42 18 -3.94 15 2.23 -28 -34 -73
Total Common Equity
-14 1.42 18 -3.94 15 2.23 -28 -34 -73
Common Stock
176 176 177 179 207 206 210 210 211
Retained Earnings
-189 -175 -159 -183 -191 -204 -238 -244 -284

Annual Metrics And Ratios for Lifecore Biomedical

This table displays calculated financial ratios and metrics derived from Lifecore Biomedical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 5/31/2015 5/29/2016 5/28/2017 5/27/2018 5/26/2019 5/31/2020 5/30/2021 5/29/2022 5/28/2023 5/26/2024 5/25/2025
DEI Shares Outstanding
26,947,394.00 27,073,243.00 27,305,179.00 27,564,428.00 29,182,631.00 29,182,178.00 29,332,832.00 29,482,538.00 30,322,169.00 - 37,025,331.00
DEI Adjusted Shares Outstanding
26,947,394.00 27,073,243.00 27,305,179.00 27,564,428.00 29,182,631.00 29,182,178.00 29,332,832.00 29,482,538.00 30,322,169.00 - 37,025,331.00
DEI Earnings Per Adjusted Shares Outstanding
0.50 -0.43 0.39 0.90 0.01 -1.31 -1.10 -3.96 -3.28 - -1.20
Growth Metrics
- - - - - - - - - - -
Revenue Growth
13.10% -11.56% -1.50% 11.59% 6.36% -71.29% -36.98% 10.31% -7.19% 24.20% 0.47%
EBITDA Growth
-23.18% -135.01% 361.59% 10.11% -22.82% -132.43% 101.04% 17,025.33% -173.41% 486.71% -124.78%
EBIT Growth
-28.56% -190.08% 180.13% 5.90% -57.09% -468.49% 24.08% 73.64% -333.31% 222.11% -161.00%
NOPAT Growth
-9.57% -222.36% 172.63% 103.53% -85.05% -667.50% 65.90% -33.64% -84.85% 43.15% -39.17%
Net Income Growth
-29.04% -183.41% 193.27% 133.43% -98.35% -9,392.21% 15.44% -261.41% 14.70% 112.07% -422.29%
EPS Growth
-29.58% -186.00% 188.37% 134.21% -98.88% -13,200.00% 16.03% -260.91% 16.37% 109.64% -484.85%
Operating Cash Flow Growth
26.48% -22.00% 43.71% -33.71% -19.01% -206.37% 196.66% -237.17% 22.80% 98.76% -180.16%
Free Cash Flow Firm Growth
-428.61% -134.42% 94.50% -1,469.50% -262.54% 77.27% 1,315.41% -111.21% 264.39% -222.81% 84.93%
Invested Capital Growth
10.89% 6.08% 4.59% 16.98% 29.63% 0.69% -62.10% 12.75% -34.62% 41.72% -1.77%
Revenue Q/Q Growth
-4.95% -4.36% -1.30% 16.99% 2.14% -72.73% 172.13% 226.62% 69.54% 5.55% -1.11%
EBITDA Q/Q Growth
-85.15% 94.45% -15.20% 34.75% -18.02% -65.82% 101.83% -41.43% -69.25% 16.78% 35.05%
EBIT Q/Q Growth
-88.41% 89.73% -22.98% 73.18% -47.07% -13.92% 17.31% -318.93% -15.04% 26.40% 25.49%
NOPAT Q/Q Growth
-93.66% 89.10% -18.78% 36.11% -61.26% -12.76% 26.12% -162.08% -10.20% 29.72% 15.57%
Net Income Q/Q Growth
-92.49% 93.66% -17.97% 17.15% -93.94% -63.88% 28.15% -83.81% 14.16% 159.51% 13.29%
EPS Q/Q Growth
0.00% 0.00% -19.15% 18.67% -96.00% -63.75% 29.03% -84.65% 14.87% 137.21% 8.63%
Operating Cash Flow Q/Q Growth
29.30% 5.54% -20.46% -26.63% -5.36% -195.49% 883.21% -39.69% -10.90% 98.05% -107.66%
Free Cash Flow Firm Q/Q Growth
-107.97% 79.21% -119.02% -13.82% 12.35% -2.18% 1,008.02% -119.07% 28.25% -5,536.27% -31.48%
Invested Capital Q/Q Growth
-0.44% 1.68% 4.58% 6.91% 0.67% 0.28% -58.92% -23.52% -36.32% -3.86% 0.09%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
12.13% 14.00% 16.86% 14.94% 14.53% 24.61% 38.60% 35.11% 27.10% 32.63% 31.27%
EBITDA Margin
5.31% -2.10% 5.59% 5.51% 4.00% -4.52% 0.07% 11.54% -9.13% 28.43% -6.84%
Operating Margin
3.42% -4.33% 3.12% 2.59% 0.98% -16.17% -8.75% -10.60% -21.11% -6.90% -13.38%
EBIT Margin
4.00% -4.07% 3.31% 3.15% 1.27% -16.29% -19.62% -4.69% -21.89% 21.52% -13.07%
Profit (Net Income) Margin
2.55% -2.40% 2.27% 4.75% 0.07% -23.86% -32.01% -104.89% -96.41% 9.37% -30.04%
Tax Burden Percent
63.92% 58.13% 75.32% 151.99% 11.29% 124.62% 108.42% 564.19% 155.74% 126.27% 100.11%
Interest Burden Percent
99.55% 101.37% 91.05% 99.46% 51.45% 117.54% 150.50% 396.53% 282.79% 34.47% 229.67%
Effective Tax Rate
36.08% 0.00% 28.50% -57.10% 41.70% 0.00% 0.00% 0.00% 0.00% 1.92% 0.00%
Return on Invested Capital (ROIC)
4.99% -5.64% 3.89% 7.14% 0.86% -4.32% -2.13% -4.86% -10.25% -6.10% -7.20%
ROIC Less NNEP Spread (ROIC-NNEP)
13.06% 1.87% 4.27% 13.22% -1.69% -16.20% -37.52% -441.05% -106.79% 15.08% -29.97%
Return on Net Nonoperating Assets (RNNOA)
1.47% 0.34% 0.96% 3.23% -0.70% -10.92% -12.79% -75.70% -151.75% 33.10% -69.21%
Return on Equity (ROE)
6.46% -5.29% 4.85% 10.37% 0.16% -15.24% -14.92% -80.56% -162.01% 27.00% -76.41%
Cash Return on Invested Capital (CROIC)
-5.33% -11.54% -0.60% -8.52% -24.95% -5.01% 87.93% -16.85% 31.61% -40.62% -5.41%
Operating Return on Assets (OROA)
6.53% -5.64% 4.44% 4.32% 1.53% -4.92% -3.79% -1.34% -8.56% 10.88% -6.83%
Return on Assets (ROA)
4.16% -3.32% 3.05% 6.53% 0.09% -7.20% -6.19% -30.06% -37.70% 4.73% -15.70%
Return on Common Equity (ROCE)
6.41% -5.25% 4.81% 10.34% 0.16% -15.24% -14.92% -80.56% -110.18% 2.15% -9.54%
Return on Equity Simple (ROE_SIMPLE)
6.28% -5.43% 4.71% 9.87% 0.15% -16.53% -15.99% -132.90% 2,353.74% 106.17% 0.00%
Net Operating Profit after Tax (NOPAT)
12 -14 10 21 3.19 -18 -6.18 -8.25 -15 -8.67 -12
NOPAT Margin
2.19% -3.03% 2.23% 4.07% 0.57% -11.32% -6.12% -7.42% -14.77% -6.76% -9.37%
Net Nonoperating Expense Percent (NNEP)
-8.06% -7.51% -0.38% -6.09% 2.55% 11.88% 35.39% 436.18% 96.54% -21.18% 22.77%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - - - -9.41%
Cost of Revenue to Revenue
87.87% 86.00% 83.14% 85.06% 85.47% 75.39% 61.40% 64.89% 72.90% 67.37% 68.73%
SG&A Expenses to Revenue
7.41% 9.68% 11.17% 9.91% 11.13% 25.41% 27.48% 31.15% 37.74% 31.55% 34.18%
R&D to Revenue
1.30% 1.52% 2.02% 2.44% 2.06% 4.74% 6.63% 7.05% 8.46% 6.69% 6.41%
Operating Expenses to Revenue
8.71% 18.33% 13.74% 12.35% 13.55% 40.77% 47.35% 45.71% 48.21% 39.52% 44.65%
Earnings before Interest and Taxes (EBIT)
22 -19 16 16 7.08 -26 -20 -5.22 -23 28 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
29 -10 26 29 22 -7.23 0.08 13 -9.43 36 -8.81
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.76 1.47 1.64 1.53 1.02 1.35 1.74 3.31 0.00 15.17 186.24
Price to Tangible Book Value (P/TBV)
3.42 2.22 2.50 2.20 1.86 2.52 1.91 4.17 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.71 0.65 0.79 0.74 0.49 1.95 3.48 2.62 2.33 1.34 1.93
Price to Earnings (P/E)
28.43 0.00 35.20 15.60 668.86 0.00 0.00 0.00 0.00 14.29 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
3.52% 0.00% 2.84% 6.41% 0.15% 0.00% 0.00% 0.00% 0.00% 7.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.67 1.38 1.53 1.42 1.01 1.19 3.41 2.38 3.08 1.96 2.49
Enterprise Value to Revenue (EV/Rev)
0.77 0.76 0.90 0.87 0.76 3.13 5.40 3.85 3.51 2.55 3.21
Enterprise Value to EBITDA (EV/EBITDA)
14.49 0.00 16.09 15.82 18.96 0.00 7,256.71 33.34 0.00 8.97 0.00
Enterprise Value to EBIT (EV/EBIT)
19.25 0.00 27.12 27.74 59.76 0.00 0.00 0.00 0.00 11.85 0.00
Enterprise Value to NOPAT (EV/NOPAT)
35.18 0.00 40.26 21.43 132.47 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
15.60 17.49 14.15 23.12 26.39 0.00 33.04 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 2.13 0.00 7.71 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.19 0.29 0.24 0.29 0.55 0.82 0.96 1.57 2.90 2.25 2.68
Long-Term Debt to Equity
0.16 0.23 0.20 0.16 0.32 0.44 0.82 0.00 2.88 2.24 2.68
Financial Leverage
0.11 0.18 0.22 0.24 0.42 0.67 0.34 0.17 1.42 2.20 2.31
Leverage Ratio
1.55 1.59 1.59 1.59 1.77 2.12 2.41 2.68 4.30 5.70 4.87
Compound Leverage Factor
1.55 1.62 1.45 1.58 0.91 2.49 3.63 10.63 12.15 1.97 11.18
Debt to Total Capital
16.19% 22.36% 19.13% 22.41% 35.55% 45.17% 48.98% 61.14% 74.34% 69.23% 72.81%
Short-Term Debt to Total Capital
3.18% 4.16% 2.81% 9.81% 14.74% 21.11% 7.33% 61.14% 0.42% 0.44% 0.00%
Long-Term Debt to Total Capital
13.01% 18.20% 16.32% 12.60% 20.80% 24.06% 41.66% 0.00% 73.91% 68.79% 72.81%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.64% 0.59% 0.55% 0.00% 0.00% 0.00% 0.00% 0.00% 28.76% 24.31% 26.43%
Common Equity to Total Capital
83.17% 77.05% 80.32% 77.59% 64.45% 54.83% 51.02% 38.86% -3.09% 6.46% 0.77%
Debt to EBITDA
1.48 -6.09 2.06 2.52 6.68 -26.31 2,585.36 10.76 -10.78 3.33 -14.41
Net Debt to EBITDA
0.99 -5.11 1.83 2.42 6.63 -26.26 2,575.19 10.68 -8.76 3.09 -13.47
Long-Term Debt to EBITDA
1.19 -4.96 1.75 1.42 3.91 -14.01 2,198.69 0.00 -10.72 3.31 -14.41
Debt to NOPAT
3.60 -4.23 5.15 3.42 46.68 -10.51 -31.40 -16.74 -6.66 -13.98 -10.52
Net Debt to NOPAT
2.41 -3.55 4.57 3.28 46.34 -10.49 -31.27 -16.62 -5.41 -13.01 -9.84
Long-Term Debt to NOPAT
2.90 -3.45 4.39 1.92 27.32 -5.60 -26.70 0.00 -6.62 -13.89 -10.52
Altman Z-Score
4.06 3.04 3.60 3.36 2.07 0.91 0.98 0.61 0.05 0.66 0.16
Noncontrolling Interest Sharing Ratio
0.79% 0.76% 0.72% 0.32% 0.00% 0.00% 0.00% 0.00% 31.99% 92.04% 87.52%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.66 1.53 1.58 1.10 0.97 0.96 1.43 0.66 2.39 2.08 2.84
Quick Ratio
1.08 1.00 1.01 0.64 0.52 0.47 0.32 0.22 1.22 1.02 1.49
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-13 -30 -1.62 -25 -92 -21 255 -29 47 -58 -9.07
Operating Cash Flow to CapEx
161.91% 52.47% 130.17% 59.06% 36.02% -70.27% 133.80% -78.45% -81.19% -1.21% -3.21%
Free Cash Flow to Firm to Interest Expense
-6.89 -14.87 -0.53 -13.07 -17.66 -4.52 25.42 -1.85 1.14 -3.19 0.00
Operating Cash Flow to Interest Expense
14.55 10.45 9.75 10.14 3.06 -3.67 1.64 -1.46 -0.42 -0.01 0.00
Operating Cash Flow Less CapEx to Interest Expense
5.56 -9.46 2.26 -7.03 -5.44 -8.89 0.41 -3.32 -0.94 -1.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.63 1.38 1.34 1.37 1.21 0.30 0.19 0.29 0.39 0.51 0.52
Accounts Receivable Turnover
11.83 10.27 10.18 10.51 9.03 2.20 1.87 3.18 3.07 4.26 4.62
Inventory Turnover
19.04 16.22 15.89 16.09 11.09 2.00 1.24 2.07 1.96 2.14 2.45
Fixed Asset Turnover
6.80 4.65 3.70 3.58 3.10 0.82 0.67 0.99 0.82 0.91 0.93
Accounts Payable Turnover
14.12 12.44 14.09 15.07 10.75 2.29 1.96 5.88 4.30 4.50 7.21
Days Sales Outstanding (DSO)
30.87 35.54 35.86 34.74 40.41 166.20 195.03 114.66 119.00 85.62 78.98
Days Inventory Outstanding (DIO)
19.17 22.50 22.97 22.69 32.92 182.14 295.36 176.75 186.27 170.69 148.92
Days Payable Outstanding (DPO)
25.85 29.33 25.90 24.23 33.95 159.73 186.42 62.11 84.96 81.17 50.59
Cash Conversion Cycle (CCC)
24.18 28.71 32.93 33.20 39.37 188.62 303.96 229.30 220.31 175.15 177.30
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
249 264 276 323 418 421 160 180 118 167 166
Invested Capital Turnover
2.28 1.86 1.74 1.75 1.51 0.38 0.35 0.66 0.69 0.90 0.77
Increase / (Decrease) in Invested Capital
24 15 12 47 96 2.89 -261 20 -62 49 -3.00
Enterprise Value (EV)
415 363 422 457 423 501 544 428 363 327 414
Market Capitalization
385 310 373 387 275 311 351 291 241 172 249
Book Value per Share
$8.11 $7.78 $8.30 $9.16 $9.26 $7.92 $6.88 $2.98 ($0.14) $0.37 $0.04
Tangible Book Value per Share
$4.18 $5.16 $5.47 $6.39 $5.08 $4.23 $6.27 $2.37 ($0.74) ($0.22) ($0.45)
Total Capital
263 273 282 326 419 421 396 226 137 175 174
Total Debt
43 61 54 73 149 190 194 138 102 121 127
Total Long-Term Debt
34 50 46 41 87 101 165 0.00 101 121 127
Net Debt
28 51 48 70 148 190 193 137 83 113 119
Capital Expenditures (CapEx)
16 40 23 33 44 24 12 29 21 18 6.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)
31 31 32 38 57 81 72 77 36 34 47
Debt-free Net Working Capital (DFNWC)
45 41 38 41 58 82 72 78 55 43 55
Net Working Capital (NWC)
37 30 30 8.69 -4.05 -7.28 43 -60 55 42 55
Net Nonoperating Expense (NNE)
-1.92 -2.99 -0.19 -3.58 2.78 20 26 108 84 -21 27
Net Nonoperating Obligations (NNO)
28 51 48 70 148 190 -42 92 83 113 119
Total Depreciation and Amortization (D&A)
7.09 9.40 11 12 15 19 20 18 13 8.86 8.03
Debt-free, Cash-free Net Working Capital to Revenue
5.80% 6.59% 6.76% 7.20% 10.16% 50.80% 71.06% 69.45% 34.93% 26.88% 36.65%
Debt-free Net Working Capital to Revenue
8.42% 8.67% 8.04% 7.75% 10.36% 51.02% 71.82% 70.34% 53.42% 33.47% 43.07%
Net Working Capital to Revenue
6.87% 6.28% 6.35% 1.66% -0.73% -4.55% 43.07% -53.84% 52.86% 32.87% 43.07%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.50 ($0.43) $0.39 $0.90 $0.01 ($1.31) ($1.12) $0.00 ($3.32) $0.40 ($1.27)
Adjusted Weighted Average Basic Shares Outstanding
26.88K 27.04M 27.28M 27.54M 28.36M 29.16M 29.29M 0.00 29.96M 30.47M 34.82M
Adjusted Diluted Earnings per Share
$0.50 ($0.43) $0.38 $0.89 $0.01 ($1.31) ($1.12) $0.00 ($3.32) $0.32 ($1.27)
Adjusted Weighted Average Diluted Shares Outstanding
27.34K 27.04M 27.65M 27.92M 28.61M 29.16M 29.29M 0.00 29.96M 36.66M 34.82M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
27.01M 27.23M 27.51M 27.74M 29.15M 29.24M 29.46M 0.00 0.00 30.90M 37.41M
Normalized Net Operating Profit after Tax (NOPAT)
12 9.36 12 9.51 4.36 -6.21 3.17 -2.40 -12 -7.05 -8.40
Normalized NOPAT Margin
2.19% 1.96% 2.63% 1.81% 0.78% -3.88% 3.14% -2.16% -11.94% -5.50% -6.52%
Pre Tax Income Margin
3.98% -4.13% 3.02% 3.13% 0.65% -19.15% -29.53% -18.59% -61.90% 7.42% -30.01%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
11.79 -9.78 5.09 8.45 1.35 -5.61 -1.97 -0.34 -0.55 1.53 0.00
NOPAT to Interest Expense
6.45 -7.27 3.43 10.95 0.61 -3.90 -0.62 -0.53 -0.37 -0.48 0.00
EBIT Less CapEx to Interest Expense
2.80 -29.69 -2.40 -8.72 -7.15 -10.83 -3.20 -2.20 -1.07 0.54 0.00
NOPAT Less CapEx to Interest Expense
-2.54 -27.18 -4.06 -6.23 -7.89 -9.12 -1.84 -2.40 -0.89 -1.47 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
1.43% -2.17% 1.55% 0.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
1.43% -2.17% 1.55% 0.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lifecore Biomedical

This table displays calculated financial ratios and metrics derived from Lifecore Biomedical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 8/27/2023 11/26/2023 2/25/2024 5/26/2024 8/25/2024 11/24/2024 2/23/2025 5/25/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
30,322,169.00 30,322,169.00 30,322,169.00 - - - - 37,025,331.00 37,466,352.00 37,509,407.00 37,853,060.00
DEI Adjusted Shares Outstanding
30,322,169.00 30,322,169.00 30,322,169.00 - - - - 37,025,331.00 37,466,352.00 37,509,407.00 37,853,060.00
DEI Earnings Per Adjusted Shares Outstanding
-0.35 0.47 0.52 - - - - -0.06 -0.43 -0.19 -1.08
Growth Metrics
- - - - - - - - - - -
Revenue Growth
3.36% 37.90% 34.55% 21.64% 0.75% 8.01% -1.54% -3.80% -6.12% -6.25% -18.60%
EBITDA Growth
-827.44% 855.61% 762.63% 120.21% -38.62% -95.10% -133.90% 856.28% 39.21% -37.71% -2,097.56%
EBIT Growth
-147.24% 426.53% 400.16% 80.99% -26.83% -105.82% -148.19% 425.72% 29.12% -66.55% -865.34%
NOPAT Growth
-163.10% 60.23% 80.71% 132.35% -34.48% 7.95% -616.54% 148.00% 59.67% -51.81% 70.85%
Net Income Growth
1.93% 211.03% 142.82% 81.97% -50.92% -146.22% -194.48% 83.81% 7.70% -436.70% -301.20%
EPS Growth
5.41% 190.70% 135.00% 89.39% -51.43% -164.10% -211.90% 84.62% 18.87% -216.67% -272.41%
Operating Cash Flow Growth
-656.49% 154.74% 87.91% 481.96% 92.28% -574.38% 184.63% -38.65% 866.72% -130.57% 16.58%
Free Cash Flow Firm Growth
-160.96% -38.04% -77.29% -182.55% 66.55% -135.42% -89.69% 113.45% 124.64% 207.91% 866.19%
Invested Capital Growth
0.00% -30.55% -6.13% 41.72% 28.61% 14.31% -4.26% -1.77% -8.74% -10.09% -30.93%
Revenue Q/Q Growth
-21.27% 22.95% 18.42% 6.11% -34.79% 31.81% 7.95% 3.67% -36.36% 47.32% -25.89%
EBITDA Q/Q Growth
-44.24% 411.97% 6.40% -95.82% -1,089.32% 111.03% -835.98% 187.55% -185.54% 173.77% -845.93%
EBIT Q/Q Growth
-20.60% 312.60% 5.70% -107.01% -704.66% 90.24% -774.51% 147.41% -275.11% 119.10% -2,282.16%
NOPAT Q/Q Growth
-29.75% 75.29% 40.79% 270.47% -639.29% 83.09% -360.90% 159.00% -187.70% 154.94% -134.83%
Net Income Q/Q Growth
72.63% 232.21% 9.95% -145.31% -129.14% 59.51% -124.76% 92.23% -1,206.02% 58.91% -551.14%
EPS Q/Q Growth
73.48% 211.43% 7.69% -133.33% -278.57% 52.83% -88.00% 95.74% -2,050.00% 55.81% -468.42%
Operating Cash Flow Q/Q Growth
-268.21% 115.46% -210.09% 663.23% -107.44% -850.23% 119.64% 345.58% -12.10% -146.57% 417.31%
Free Cash Flow Firm Q/Q Growth
-328.88% 148.50% -83.69% -555.94% 7.25% 48.64% 104.75% 525.35% 61.64% 74.30% 167.59%
Invested Capital Q/Q Growth
7.01% 18.21% 16.53% -3.86% -2.89% 5.06% -2.40% 0.09% -11.08% 3.51% -25.02%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
11.12% 33.02% 33.31% 45.59% 21.81% 34.04% 28.01% 38.37% 19.24% 35.34% 26.96%
EBITDA Margin
-26.16% 66.39% 59.65% 2.37% -36.00% 3.01% -20.54% 17.34% -23.31% 11.68% -117.51%
Operating Margin
-35.13% -4.92% -2.51% 5.67% -46.89% -6.02% -25.68% 14.62% -20.14% 7.51% -3.53%
EBIT Margin
-35.01% 60.53% 54.03% -3.57% -44.07% -3.26% -26.44% 12.09% -33.27% 4.31% -127.02%
Profit (Net Income) Margin
-43.85% 47.16% 43.78% -18.70% -65.70% -20.18% -42.01% -3.15% -64.59% -18.02% -158.30%
Tax Burden Percent
85.88% 100.29% 104.20% 99.16% 99.85% 100.66% 99.95% 102.96% 100.29% 100.38% 100.13%
Interest Burden Percent
145.88% 77.68% 77.77% 527.94% 149.31% 614.11% 158.96% -25.28% 193.56% -416.08% 124.46%
Effective Tax Rate
0.00% -0.46% 1.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-40.65% -3.06% -1.68% 3.58% -29.30% -3.46% -13.80% 7.86% -11.60% 4.07% -2.10%
ROIC Less NNEP Spread (ROIC-NNEP)
-50.17% 9.68% 12.94% -5.21% -36.62% -8.25% -21.07% 3.70% -20.99% -2.36% -32.98%
Return on Net Nonoperating Assets (RNNOA)
-187.66% 20.49% 22.13% -11.44% -122.93% -17.52% -45.86% 8.54% -86.83% -7.70% -335.13%
Return on Equity (ROE)
-228.32% 17.43% 20.45% -7.86% -152.23% -20.98% -59.66% 16.40% -98.43% -3.63% -337.23%
Cash Return on Invested Capital (CROIC)
-230.18% 27.09% -0.57% -40.62% -33.14% -18.75% -4.07% -5.41% 4.46% 4.95% 31.14%
Operating Return on Assets (OROA)
-14.83% 25.91% 27.22% -1.81% -22.99% -1.70% -14.24% 6.32% -17.94% 2.23% -65.03%
Return on Assets (ROA)
-18.58% 20.19% 22.06% -9.45% -34.27% -10.54% -22.63% -1.64% -34.83% -9.30% -81.05%
Return on Common Equity (ROCE)
116.59% 11.31% 8.03% -0.63% 40.32% -3.47% -11.12% 2.05% 52.87% 0.89% 954.36%
Return on Equity Simple (ROE_SIMPLE)
732.68% 0.00% -114.15% 0.00% -166.00% -92.25% -2,003.28% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.03 -1.49 -0.88 1.50 -8.11 -1.37 -6.32 3.73 -3.27 1.80 -0.63
NOPAT Margin
-24.59% -4.94% -2.47% 3.97% -32.82% -4.21% -17.98% 10.23% -14.10% 5.26% -2.47%
Net Nonoperating Expense Percent (NNEP)
9.51% -12.74% -14.61% 8.79% 7.33% 4.80% 7.27% 4.17% 9.39% 6.43% 30.88%
Return On Investment Capital (ROIC_SIMPLE)
- -1.34% -0.65% - - -1.01% -5.01% 2.91% -2.74% 1.50% -0.72%
Cost of Revenue to Revenue
88.88% 66.98% 66.69% 54.41% 78.19% 65.96% 71.99% 61.63% 80.76% 64.66% 73.04%
SG&A Expenses to Revenue
37.50% 30.99% 27.58% 32.27% 59.85% 34.15% 28.71% 22.09% 34.14% 23.33% 24.88%
R&D to Revenue
8.75% 6.96% 6.08% 5.70% 8.85% 5.91% 5.82% 5.77% 5.25% 4.50% 5.61%
Operating Expenses to Revenue
46.25% 37.94% 35.82% 39.92% 68.69% 40.05% 53.69% 23.75% 39.38% 27.83% 30.49%
Earnings before Interest and Taxes (EBIT)
-8.58 18 19 -1.35 -11 -1.06 -9.30 4.41 -7.72 1.47 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.42 20 21 0.90 -8.89 0.98 -7.22 6.32 -5.41 3.99 -30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 160.25 13.84 15.17 0.00 14.62 93.19 186.24 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.44 2.03 2.01 1.34 1.44 1.73 1.59 1.93 1.09 1.57 2.09
Price to Earnings (P/E)
0.00 0.00 0.00 14.29 28.33 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 7.00% 3.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.13 2.52 2.31 1.96 2.17 2.24 2.24 2.49 2.14 2.51 3.81
Enterprise Value to Revenue (EV/Rev)
3.78 3.34 3.29 2.55 2.73 2.91 2.85 3.21 2.48 3.07 3.66
Enterprise Value to EBITDA (EV/EBITDA)
0.00 63.18 13.15 8.97 10.33 25.45 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 18.33 11.85 13.88 63.55 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 47.00 5,359.48 138.16 0.00 61.79 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 7.63 0.00 0.00 0.00 0.00 0.00 0.00 45.66 48.05 10.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
4.06 2.59 1.97 2.25 3.24 2.00 2.61 2.68 7.11 9.58 -7.18
Long-Term Debt to Equity
4.04 2.57 1.96 2.24 3.22 1.99 2.61 2.68 7.11 9.58 -7.18
Financial Leverage
3.74 2.12 1.71 2.20 3.36 2.12 2.18 2.31 4.14 3.26 10.16
Leverage Ratio
9.25 4.51 3.65 5.70 7.45 4.91 4.53 4.87 7.84 6.39 18.53
Compound Leverage Factor
13.49 3.50 2.84 30.11 11.13 30.14 7.20 -1.23 15.17 -26.60 23.06
Debt to Total Capital
80.25% 72.16% 66.32% 69.23% 76.41% 66.72% 72.34% 72.81% 87.67% 90.54% 116.18%
Short-Term Debt to Total Capital
0.57% 0.51% 0.44% 0.44% 0.46% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
79.68% 71.65% 65.88% 68.79% 75.94% 66.29% 72.34% 72.81% 87.67% 90.54% 116.18%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
29.83% 26.91% 23.66% 24.31% 25.95% 24.68% 26.36% 26.43% 29.20% 29.49% 37.13%
Common Equity to Total Capital
-10.08% 0.93% 10.02% 6.46% -2.35% 8.60% 1.30% 0.77% -16.87% -20.03% -53.30%
Debt to EBITDA
-6.45 18.48 3.84 3.33 3.76 8.01 -9.14 -14.41 -27.75 -19.91 -4.43
Net Debt to EBITDA
-5.94 17.94 3.74 3.09 3.60 7.38 -8.74 -13.47 -23.85 -17.68 -3.79
Long-Term Debt to EBITDA
-6.41 18.35 3.82 3.31 3.74 7.96 -9.14 -14.41 -27.75 -19.91 -4.43
Debt to NOPAT
-5.68 -6.74 -9.48 -13.98 -10.96 -13.93 -8.67 -10.52 -20.43 -16.81 -20.93
Net Debt to NOPAT
-5.23 -6.54 -9.23 -13.01 -10.49 -12.83 -8.30 -9.84 -17.56 -14.93 -17.92
Long-Term Debt to NOPAT
-5.64 -6.69 -9.42 -13.89 -10.89 -13.84 -8.67 -10.52 -20.43 -16.81 -20.93
Altman Z-Score
0.16 0.55 0.82 0.28 0.04 0.36 0.14 0.45 -0.31 -0.05 -0.76
Noncontrolling Interest Sharing Ratio
151.07% 35.12% 60.73% 92.04% 126.49% 83.48% 81.36% 87.52% 153.71% 124.58% 383.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.34 1.91 2.07 2.08 1.83 2.32 2.71 2.84 3.79 3.87 3.84
Quick Ratio
1.00 0.83 0.94 1.02 0.76 1.13 1.32 1.49 1.96 2.20 2.00
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-132 64 10 -48 -44 -23 1.08 6.73 11 19 51
Operating Cash Flow to CapEx
-164.80% 30.23% -22.27% 327.65% -18.96% -247.37% 21.99% 254.98% 420.39% -426.71% 761.62%
Free Cash Flow to Firm to Interest Expense
-33.50 15.71 0.00 -8.22 -8.22 -4.15 0.00 0.00 1.48 2.45 6.26
Operating Cash Flow to Interest Expense
-2.12 0.32 0.00 1.49 -0.12 -1.12 0.00 0.00 0.64 -0.28 0.86
Operating Cash Flow Less CapEx to Interest Expense
-3.40 -0.73 0.00 1.04 -0.75 -1.57 0.00 0.00 0.49 -0.35 0.74
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.42 0.43 0.50 0.51 0.52 0.52 0.54 0.52 0.54 0.52 0.51
Accounts Receivable Turnover
3.91 3.41 3.81 4.26 4.96 4.33 4.42 4.62 5.71 4.12 4.91
Inventory Turnover
1.90 1.40 2.02 2.14 2.01 2.11 2.34 2.45 2.52 2.71 2.66
Fixed Asset Turnover
0.76 0.86 0.91 0.91 0.90 0.89 0.95 0.93 0.93 0.91 0.95
Accounts Payable Turnover
5.06 3.55 5.86 4.50 4.98 5.01 7.51 7.21 7.03 7.79 10.35
Days Sales Outstanding (DSO)
93.36 107.03 95.84 85.62 73.55 84.38 82.55 78.98 63.89 88.65 74.31
Days Inventory Outstanding (DIO)
191.81 260.52 180.87 170.69 181.19 172.73 156.29 148.92 144.78 134.75 137.31
Days Payable Outstanding (DPO)
72.19 102.91 62.32 81.17 73.28 72.79 48.59 50.59 51.91 46.87 35.25
Cash Conversion Cycle (CCC)
212.97 264.64 214.39 175.15 181.46 184.33 190.25 177.30 156.76 176.53 176.37
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
126 149 173 167 162 170 166 166 148 153 115
Invested Capital Turnover
1.65 0.62 0.68 0.90 0.89 0.82 0.77 0.77 0.82 0.77 0.85
Increase / (Decrease) in Invested Capital
126 -65 -11 49 36 21 -7.40 -3.00 -14 -17 -51
Enterprise Value (EV)
394 375 400 327 351 381 372 414 316 384 437
Market Capitalization
254 228 245 172 185 226 208 249 139 197 249
Book Value per Share
($0.45) $0.05 $0.58 $0.37 ($0.13) $0.50 $0.06 $0.04 ($0.76) ($0.91) ($1.94)
Tangible Book Value per Share
($1.04) ($0.55) ($0.01) ($0.22) ($0.71) ($0.09) ($0.43) ($0.45) ($1.13) ($1.28) ($2.31)
Total Capital
134 152 176 175 167 180 171 174 169 170 138
Total Debt
108 110 117 121 128 120 124 127 148 154 160
Total Long-Term Debt
107 109 116 121 127 119 124 127 148 154 160
Net Debt
99 107 114 113 122 110 119 119 127 137 137
Capital Expenditures (CapEx)
5.05 4.26 6.37 2.64 3.39 2.47 5.46 2.10 1.12 0.51 0.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)
40 34 37 34 29 38 48 47 36 45 40
Debt-free Net Working Capital (DFNWC)
48 37 40 43 34 47 53 55 57 62 63
Net Working Capital (NWC)
47 36 39 42 34 47 53 55 57 62 63
Net Nonoperating Expense (NNE)
4.72 -16 -17 8.59 8.12 5.20 8.45 4.88 12 7.95 39
Net Nonoperating Obligations (NNO)
99 106 114 113 122 110 119 119 127 137 137
Total Depreciation and Amortization (D&A)
2.17 1.77 2.01 2.25 1.99 2.04 2.08 1.91 2.31 2.52 2.41
Debt-free, Cash-free Net Working Capital to Revenue
37.99% 30.27% 30.49% 26.88% 22.51% 28.95% 36.59% 36.65% 28.54% 35.82% 33.20%
Debt-free Net Working Capital to Revenue
46.29% 33.14% 33.01% 33.47% 26.81% 36.18% 40.75% 43.07% 44.87% 49.61% 52.51%
Net Working Capital to Revenue
45.55% 32.45% 32.38% 32.87% 26.21% 35.59% 40.75% 43.07% 44.87% 49.61% 52.51%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.35) $0.47 $0.51 ($0.23) ($0.53) ($0.25) ($0.47) ($0.02) ($0.43) ($0.19) ($1.08)
Adjusted Weighted Average Basic Shares Outstanding
30.40M 30.46M 30.49M 30.47M 30.86M 34.36M 37.02M 34.82M 37.48M 37.57M 37.85M
Adjusted Diluted Earnings per Share
($0.35) $0.39 $0.42 ($0.14) ($0.53) ($0.25) ($0.47) ($0.02) ($0.43) ($0.19) ($1.08)
Adjusted Weighted Average Diluted Shares Outstanding
30.40M 36.42M 36.61M 36.66M 30.86M 34.36M 37.02M 34.82M 37.48M 37.57M 37.85M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 30.90M 30.90M 37.03M 37.03M 37.41M 37.51M 37.85M 37.91M
Normalized Net Operating Profit after Tax (NOPAT)
-6.03 -1.04 -0.12 2.02 -8.11 -1.37 -1.61 3.73 -3.27 1.80 -0.63
Normalized NOPAT Margin
-24.59% -3.44% -0.34% 5.33% -32.82% -4.21% -4.57% 10.23% -14.10% 5.26% -2.47%
Pre Tax Income Margin
-51.06% 47.02% 42.02% -18.85% -65.80% -20.05% -42.04% -3.06% -64.40% -17.95% -158.10%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-2.18 4.48 0.00 -0.23 -2.03 -0.19 0.00 0.00 -1.05 0.19 -3.97
NOPAT to Interest Expense
-1.53 -0.37 0.00 0.26 -1.51 -0.25 0.00 0.00 -0.45 0.23 -0.08
EBIT Less CapEx to Interest Expense
-3.46 3.43 0.00 -0.69 -2.66 -0.65 0.00 0.00 -1.20 0.12 -4.08
NOPAT Less CapEx to Interest Expense
-2.81 -1.41 0.00 -0.20 -2.14 -0.70 0.00 0.00 -0.60 0.17 -0.19
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lifecore Biomedical’s latest quarter showed meaningful operating improvement, but the balance sheet and cash-flow trends remain challenging. Revenue increased to $34.2 million in Q2 2026 from $23.2 million in Q1, a 47% sequential increase. Gross profit rose to $12.1 million, lifting the gross margin to approximately 35.3% from 19.2% in the prior quarter. The company also returned to positive operating income of $2.6 million, compared with a $4.7 million operating loss in Q1.

The bottom line improved sequentially, although Lifecore remained unprofitable. Net loss narrowed to $6.2 million from $15.0 million in Q1, while the loss attributable to common shareholders was $7.1 million, or $0.19 per diluted share. Preferred dividends contributed approximately $1.0 million to the loss attributable to common shareholders.

Despite the improvement in reported earnings, cash generation weakened. Operating cash flow fell to negative $2.2 million in Q2 from positive cash flow of $4.7 million in Q1. Q2 also marked a reversal from positive operating cash flow in Q3 and Q4 of fiscal 2025. Working-capital changes were a significant drag, with accounts receivable increasing by approximately $11.0 million during the quarter, while inventory declined by about $2.7 million.

Lifecore ended Q2 with $17.2 million of cash, down from $20.8 million at the end of Q1. Capital expenditures were relatively modest at $513,000, but the company still reported a $3.6 million net decline in cash. Financing activity was nearly neutral because $28.0 million of new debt issuance was largely offset by $28.2 million of debt repayments.

The balance sheet remains a key risk for investors. Long-term debt increased to $154.1 million from $147.8 million in Q1 and $124.0 million in Q3 2025. Total liabilities reached $213.4 million, while total common equity was negative $34.1 million. Current assets of $83.7 million exceed current liabilities of $21.6 million, but the company’s relatively small cash balance compared with its debt load and ongoing losses leaves limited room for execution setbacks.

  • Revenue momentum improved: Q2 revenue rose 47% sequentially to $34.2 million, approaching the $36.4 million reported in Q4 2025.
  • Gross margins recovered: Gross margin increased to approximately 35.3% from 19.2% in Q1, indicating better production economics or product mix.
  • Operating performance turned positive: Lifecore generated $2.6 million of operating income in Q2 after reporting a $4.7 million operating loss in Q1.
  • Net losses narrowed: Consolidated net loss improved by approximately $8.8 million sequentially, from $15.0 million to $6.2 million.
  • Inventory declined: Inventory fell to $25.5 million from $28.2 million at the end of Q1, potentially reducing working-capital pressure.
  • Liquidity remains adequate on a current basis: Current assets were approximately 3.9 times current liabilities, although much of the current-asset base consists of receivables and inventory rather than cash.
  • Operating cash flow deteriorated: Cash flow from operations swung to negative $2.2 million in Q2 from positive $4.7 million in Q1, raising questions about the durability of the earnings improvement.
  • Cash reserves declined: Cash and equivalents fell 17% sequentially to $17.2 million, while the company continued to report net losses.
  • Debt burden increased: Long-term debt has risen substantially from $107.1 million in Q1 2024 to $154.1 million in Q2 2026, and Q2 interest expense was $7.8 million—greater than operating income.
  • Common equity is negative: Total common equity was negative $34.1 million, reflecting accumulated retained losses and increasing financial risk for common shareholders.

Overall, Q2 2026 provided evidence of an operational recovery, particularly through stronger revenue, gross margins and operating income. However, investors should focus on whether Lifecore can convert that improvement into consistent positive operating cash flow while reducing its debt and interest burden. Until those trends improve, the stock remains exposed to refinancing, dilution and execution risks.

11/17/26 12:44 PM ETAI Generated. May Contain Errors.

Lifecore Biomedical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lifecore Biomedical's fiscal year ends in May. Their fiscal year 2025 ended on May 25, 2025.

Lifecore Biomedical's net income appears to be on a downward trend, with a most recent value of -$38.72 million in 2025, compared with $13.73 million in 2015. The previous period was $12.01 million in 2024. Find out what analysts predict for Lifecore Biomedical in the coming months.

Lifecore Biomedical's total operating income in 2025 was -$17.25 million, based on the following breakdown:
  • Total Gross Profit: $40.30 million
  • Total Operating Expenses: $57.54 million

Over the last 10 years, Lifecore Biomedical's total revenue changed from $539.26 million in 2015 to $128.87 million in 2025, a change of -76.1%.

In the past 10 quarters, Lifecore Biomedical's cash and equivalents has ranged from $3.07 million in Q3 2024 to $23.04 million in Q3 2026, and is currently $23.04 million as of their latest financial filing in Q3 2026.

Lifecore Biomedical had total debt of $127.00 million at the end of 2025, a 4.7% increase from 2024, and a 198.7% increase since 2015.

Over the last 10 years, Lifecore Biomedical's book value per share changed from 8.11 in 2015 to 0.04 in 2025, a change of -99.6%.



Financial statements for NASDAQ:LFCR last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners